A panelist discusses how evolving imaging and the approval of NT-501 therapy are transforming macular telangiectasia type 2 from a diagnostic challenge into a treatable condition.
From Monitoring to Treatment: Transforming the Standard of Care in Macular Telangiectasia
A panelist discusses how strategic eye selection and proactive patient counseling optimize success and satisfaction with NT-501 implantation for bilateral MacTel type 2.
A panelist discusses how individualized imaging-based decisions guide when to initiate NT-501 therapy in both early and advanced stages of MacTel type 2.
A panelist discusses how successful NT-501 integration in MacTel care requires both strategic eye selection and overcoming financial and institutional barriers.
A panelist discusses how careful timing, patient education, and bilateral treatment planning strengthen real-world NT-501 management for MacTel type 2.
Advertisement
Advertisement
Trending on Modern Retina
1
Corza Medical announces launch of the SensorTek ROP Kit
2
AGC Biologics to manufacture AAVantgarde’s dual-vector gene therapies, AVB-039 and AAVB-081
3
FLORetina Congress celebrates 10 years with joint World Retinopathy of Prematurity meeting
4
EyePoint receives second consecutive positive recommendation from DSMC
5
